Massive data pool aims to crack childhood Leukemia's toughest cases
NCT ID NCT07150676
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will gather and combine medical and genetic data from 2,000 children with acute myeloid leukemia (AML) across France. The goal is to find hidden patterns that predict which patients are most likely to relapse. By creating a large, shared database, researchers hope to improve survival and reduce relapse rates for this rare childhood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better identify children with AML who are at high risk of relapse, leading to more personalized treatment plans and improved survival rates.
- What could go wrong
- This is an observational study that does not test a new treatment. It relies on existing data, so it may not directly change outcomes. Results may take years to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- AI platform aims to unlock Real-World cancer data on a massive scale
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?